Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 553,600 shares, a decrease of 23.0% from the March 15th total of 719,400 shares. Approximately 3.7% of the shares of the company are short sold. Based on an average daily volume of 6,590,000 shares, the short-interest ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Azitra stock. Virtu Financial LLC grew its position in Azitra, Inc. (NYSEAMERICAN:AZTR) by 196.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 63,180 shares of the company’s stock after purchasing an additional 41,866 shares during the period. Virtu Financial LLC owned approximately 0.83% of Azitra worth $27,000 as of its most recent SEC filing. 11.16% of the stock is owned by hedge funds and other institutional investors.

Azitra Stock Performance

AZTR stock traded down $0.03 during midday trading on Friday, reaching $0.29. The company had a trading volume of 367,801 shares, compared to its average volume of 2,541,506. The stock has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.48. Azitra has a fifty-two week low of $0.23 and a fifty-two week high of $12.00.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.